The background image is
ALS Clinic and Research Center
The experts at the Penn State Health ALS Clinic and Research Center provide a definitive diagnosis and offer comprehensive, multidisciplinary care that provides treatment and support to optimize dignity, independence, and quality of life. Research is an essential part of the clinic. The clinic and research center is funded by ALS United Mid-Atlantic, the Harriett H. and Paul G. Campbell Research Fund for ALS, and by private donations from many individuals and groups. Learn more about our comprehensive patient care.
The research studies are focused on three main areas, with opportunities for individuals with ALS and related motor neuron disorders to participate in clinical studies to help advance knowledge and treatment:
- Treatment trials of medications that show promise for slowing or halting the course of ALS disease progression
- The use of technology to assess speech, swallowing, breathing, walking and other essential functions in persons with ALS
- Improving the understanding of ALS and other motor neuron diseases, optimizing care and reducing the burden on persons with ALS and their caregivers
The clinic and research center is recognized by the ALS Association as a Certified Treatment Center of Excellence that evaluates and treats ALS and related conditions. About 100 new patients with ALS are diagnosed at the center every year and more than 230 are followed long-term at any given time.
Treatment trials of medications
Treatment trials of medications that show promise for slowing or halting the course of ALS disease progression
An Intermediate Expanded Access Protocol with CNMAu8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
This is the expanded access protocol supported by the funding made available by the Federal “ACT for ALS.” The purpose of the study is to provide access to the investigational product CNM-Au8 (Clene Nanomedicine) for those diagnosed with ALS. Please note that Penn State has a limited number of spots for participation.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
HEALEY ALS Platform Trial
The HEALEY ALS Platform Trial is a multicenter, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. The trial is designed as a perpetual platform trial. This means that there is a single Master Protocol determining the conduct of the trial.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
The use of technology
The use of technology to assess speech, swallowing, breathing, walking and other essential functions in persons with ALS
Digital assessment of speech and fine motor control in motor neuron disease
This study includes collection of digital speech and fine motor control assessment data at a single study visit. Features extracted from this data will be compared with standard clinical disease outcome measures and also the features derived from control participant data. We will use these comparisons to explore the use of these digital assessments in capturing the range of functional changes in motor neuron disease. This is a single-session study that measures speech and fine motor function using digital tablet-based assessments. Patients with motor neuron disease and age-matched healthy controls will be enrolled. Sessions take approximately one hour.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Augmented Reality: Perceptions, Performance, and Language Enhancement
This is a single-center feasibility study assessing the Apple Vision Pro as a device for augmentative and alternative communication in patients with Amyotrophic Lateral Sclerosis experiencing impaired communication. Participants will visit the study site once for approximately 1.5 hours. During the session, participants will complete questionnaires about their medical history, undergo an eye exam, and use an augmented reality headset that tracks the motion of the eyes to communicate. Participants and their caregivers will complete a single visit at the Hershey Medical Center lasting approximately 1.5 hours. During this time, they will undergo an eye exam, answer a set of questionnaires, and use an augmented reality (AR) headset that tracks eye-gaze to communicate.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
A multisensory evoked potential brain-computer interface for communication in ALS
A brain-computer interface (BCI) is a device that has the potential to restore communication by direct translation of brain signals. The BCI used in this study, the P300 Speller, relies on the generation of a P300 evoked potential when a user is presented a rare and unpredictable target stimulus amidst a larger pool of non-target stimuli. This evoked potential is used to perform selections on the computer. Those with advanced ALS demonstrate decreased capacity for BCI control using the P300 speller. With this study, we aim to use a combination of eye tracking and sensory testing to quantify sensory and cognitive processes necessary for the generation of a P300 response. We will test the performance of a multisensory P300 spelling task, where brain potentials are evoked using a combination of visual, auditory, and tactile stimuli. The goal is to demonstrate the perceptual benefits of multisensory integration and generate evidence for its use in this patient group.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Improving the understanding of ALS
Improving the Understanding of ALS
ALL ALS – ASSESS
ALL ALS is a multi-institutional ALS Clinical Research Consortium funded by the National Institutes of Health (NIH). This study will follow symptomatic ALS participants and control participants for 2 years, measuring a wide range of ALS outcome measures and gathering long term survival data.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
ALL ALS – PREVENT
ALL ALS is a multi-institutional ALS Clinical Research Consortium funded by the National Institutes of Health (NIH). The primary purpose of this study is to collect samples and health information from individuals who are genetically at risk for ALS to better understand ALS and how the disease progresses.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
The Impact of Personalized Prognostic Information for Patients with Amyotrophic Lateral Sclerosis
This study will attempt to determine if patients with ALS wish to receive personalized survival predictions, which patients choose to receive this information, how survival information influences patients’ decisions, as well as if and how predictions benefit patient well-being over time. The overall hypothesis is that patients with ALS who choose to receive personalized predictions would use the information to guide advanced care planning and goals of care discussions, and that with appropriate emotional, mental health, and spiritual support the benefits they receive from the predictions would outweigh the potential harms.
For more information, interested individuals should contact our research team at nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Determining ultrasonographic cross sectional area reference values for vagus and phrenic nerves in patients with motor neuron disease and assess their role as a potential predictor of disease progression
The purpose of this study is to determine ultrasonographic cross sectional area reference values for vagus and phrenic nerves in patients with motor neuron disease and assess their role as a potential predictor of disease progression. Phrenic and vagus nerve will be affected during the course of disease and cause bulbar and respiratory symptoms. We are also recruiting healthy volunteers to participate in this study. They will have 1 ultrasound done so that we can compare our findings to better help us in identifying bulbar and respiratory changes in patients with motor neuron disease.
For more information, interested individuals should contact our research team at nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Treatment trials of medications that show promise for slowing or halting the course of ALS disease progression
An Intermediate Expanded Access Protocol with CNMAu8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
This is the expanded access protocol supported by the funding made available by the Federal “ACT for ALS.” The purpose of the study is to provide access to the investigational product CNM-Au8 (Clene Nanomedicine) for those diagnosed with ALS. Please note that Penn State has a limited number of spots for participation.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
HEALEY ALS Platform Trial
The HEALEY ALS Platform Trial is a multicenter, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. The trial is designed as a perpetual platform trial. This means that there is a single Master Protocol determining the conduct of the trial.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
The use of technology to assess speech, swallowing, breathing, walking and other essential functions in persons with ALS
Digital assessment of speech and fine motor control in motor neuron disease
This study includes collection of digital speech and fine motor control assessment data at a single study visit. Features extracted from this data will be compared with standard clinical disease outcome measures and also the features derived from control participant data. We will use these comparisons to explore the use of these digital assessments in capturing the range of functional changes in motor neuron disease. This is a single-session study that measures speech and fine motor function using digital tablet-based assessments. Patients with motor neuron disease and age-matched healthy controls will be enrolled. Sessions take approximately one hour.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Augmented Reality: Perceptions, Performance, and Language Enhancement
This is a single-center feasibility study assessing the Apple Vision Pro as a device for augmentative and alternative communication in patients with Amyotrophic Lateral Sclerosis experiencing impaired communication. Participants will visit the study site once for approximately 1.5 hours. During the session, participants will complete questionnaires about their medical history, undergo an eye exam, and use an augmented reality headset that tracks the motion of the eyes to communicate. Participants and their caregivers will complete a single visit at the Hershey Medical Center lasting approximately 1.5 hours. During this time, they will undergo an eye exam, answer a set of questionnaires, and use an augmented reality (AR) headset that tracks eye-gaze to communicate.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
A multisensory evoked potential brain-computer interface for communication in ALS
A brain-computer interface (BCI) is a device that has the potential to restore communication by direct translation of brain signals. The BCI used in this study, the P300 Speller, relies on the generation of a P300 evoked potential when a user is presented a rare and unpredictable target stimulus amidst a larger pool of non-target stimuli. This evoked potential is used to perform selections on the computer. Those with advanced ALS demonstrate decreased capacity for BCI control using the P300 speller. With this study, we aim to use a combination of eye tracking and sensory testing to quantify sensory and cognitive processes necessary for the generation of a P300 response. We will test the performance of a multisensory P300 spelling task, where brain potentials are evoked using a combination of visual, auditory, and tactile stimuli. The goal is to demonstrate the perceptual benefits of multisensory integration and generate evidence for its use in this patient group.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Improving the Understanding of ALS
ALL ALS – ASSESS
ALL ALS is a multi-institutional ALS Clinical Research Consortium funded by the National Institutes of Health (NIH). This study will follow symptomatic ALS participants and control participants for 2 years, measuring a wide range of ALS outcome measures and gathering long term survival data.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
ALL ALS – PREVENT
ALL ALS is a multi-institutional ALS Clinical Research Consortium funded by the National Institutes of Health (NIH). The primary purpose of this study is to collect samples and health information from individuals who are genetically at risk for ALS to better understand ALS and how the disease progresses.
Contact: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
The Impact of Personalized Prognostic Information for Patients with Amyotrophic Lateral Sclerosis
This study will attempt to determine if patients with ALS wish to receive personalized survival predictions, which patients choose to receive this information, how survival information influences patients’ decisions, as well as if and how predictions benefit patient well-being over time. The overall hypothesis is that patients with ALS who choose to receive personalized predictions would use the information to guide advanced care planning and goals of care discussions, and that with appropriate emotional, mental health, and spiritual support the benefits they receive from the predictions would outweigh the potential harms.
For more information, interested individuals should contact our research team at nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Determining ultrasonographic cross sectional area reference values for vagus and phrenic nerves in patients with motor neuron disease and assess their role as a potential predictor of disease progression
The purpose of this study is to determine ultrasonographic cross sectional area reference values for vagus and phrenic nerves in patients with motor neuron disease and assess their role as a potential predictor of disease progression. Phrenic and vagus nerve will be affected during the course of disease and cause bulbar and respiratory symptoms. We are also recruiting healthy volunteers to participate in this study. They will have 1 ultrasound done so that we can compare our findings to better help us in identifying bulbar and respiratory changes in patients with motor neuron disease.
For more information, interested individuals should contact our research team at nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Faculty
Staff
Contact us
To contact any of our staff members: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
Contact us
To contact any of our staff members: nervemuscle@pennstatehealth.psu.edu or 717-531-8ALS (8257)
The background image is
We have developed a number of resources that can be used by ALS health care professionals to assess patients and their caregivers. For questions or if you need additional information on these instruments, please contact nervemuscle@pennstatehealth.psu.edu.
Support for Caregivers
Download our ALS Caregiver Assessment
ALS and frontotemporal dementia (FTD)
Download our ALS/FTD Caregiver Assessment
Download the Cognitive Intervention Program Presentation
Improving end-of-life care and decision making
Download the Communication and Treatment Preference Assessment
Philanthropic support is important to the ALS Clinic and Research Center. Tax-deductible gifts to help advance ALS research and care may be made via the Penn State College of Medicine Office of Development and Alumni Relations.
Did you know you can make a gift through your will to support ALS Research?
To learn more, please contact Owen Thomas, our ALS Gift Officer, at 717-531-8497 or oit1@psu.edu.
Contact Us
For more information about ALS research, or to speak with a research coordinator, please call 717-531-8ALS (8257) or e-mail nervemuscle@pennstatehealth.psu.edu.